Chardan raised the firm’s price target on Palvella Therapeutics (PVLA) to $174 from $110 and keeps a Buy rating on the shares after the company reported topline data for QTORIN rapamycin in the Phase 2 TOIVA trial in cutaneous venous malformations. The efficacy signals “handily exceed” Palvella’s previously-discussed internal threshold of 30%, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $190 from $105 at Truist
- Promising Clinical Data and Market Potential Drive Buy Rating for Palvella Therapeutics’ QTORIN Rapamycin
- Palvella Therapeutics price target raised to $200 from $190 at H.C. Wainwright
- Palvella price target raised to $210 from $200 at Cantor Fitzgerald
- Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer